BlackRock Fund Advisors recently announced the acquisition of new stake in Aravive Inc. (NASDAQ:ARAV). The institutional investor has increased its shareholding in the Healthcare company by 54.52% to 0.31 million shares with purchase of 0.11 million shares. This fresh investment now brings its stake to 0.43% valued currently at $46810.0. In addition, Geode Capital Management LLC raised its holdings by 88841.0 to 0.3 million shares. And Renaissance Technologies LLC has lifted its position by 40.29% or 61532.0 shares – to 0.21 million shares.
With over 5.41 million Aravive Inc. (ARAV) shares trading Monday and a closing price of $0.15 on the day, the dollar volume was approximately $0.81 million. The shares have shown a negative half year performance of -92.14% and its price on 09/18/23 lost nearly -3.75%. Currently, there are 75.73M common shares owned by the public and among those 45.10M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for ARAV have a consensus price objective of $5.13. The analysts have set the share’s price value over the next 12 months at a high of $10.00 and a low of $0.25. But an upside of 98.5% will see the stock hit the forecast high price target while median target price for the stock is $5.13.
Insiders at the company have transacted a total of 8 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 8 of these insider trades were purchases, accounting for 17,838,891 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Aravive Inc. are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market ETF owns 0.78 million shares of the company’s stock, all valued at over $0.12 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.22% of the shares outstanding.
Shares of Aravive Inc. (NASDAQ: ARAV) opened at $0.1502, down -$0.01 from a prior closing price of $0.16. However, the script later moved the day high at 0.1677, down -3.75%. The company’s stock has a 5-day price change of 4.05% and -89.93% over the past three months. ARAV shares are trading -88.33% year to date (YTD), with the 12-month market performance down to -85.05% lower. It has a 12-month low price of $0.11 and touched a high of $2.46 over the same period. ARAV has an average intraday trading volume of 6.93 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.26%, -77.49%, and -89.31% respectively.
Institutional ownership of Aravive Inc. (NASDAQ: ARAV) shares accounts for 6.70% of the company’s 75.73M shares outstanding. Mutual fund holders own 2.34%, while other institutional holders and individual stakeholders account for 41.60% and 19.58% respectively.
It has a market capitalization of $10.01M and a beta (3y monthly) value of 2.38. The earnings-per-share (ttm) stands at -$1.45. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.34% over the week and 16.01% over the month.
Analysts forecast that Aravive Inc. (ARAV) will achieve an EPS of -$0.1 for the current quarter, -$0.06 for the next quarter and -$0.08 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.16 while analysts give the company a high EPS estimate of -$0.05. Comparatively, EPS for the current quarter was -$0.51 a year ago. Earnings per share for the fiscal year are expected to decrease by -7.60%, and 86.90% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Aravive Inc. (ARAV) as a “Hold” at a consensus score of 3.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 4 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ARAV, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on April 17, 2023, with the firm’s price target at $12.